Retrospective financial analysis of a herpes zoster vaccination program from an independent community pharmacy perspective

Journal of the American Pharmacists Association

Volumn 49, Issue 1, 2009, Pages 12-17

  Wood, Heidi M ^a   McDonough, Randal P ^b   Doucette, William R ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Clinical Services   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Community pharmacy; Cost benefit analysis; Financial; Herpes zoster; Pharmacist; Vaccination

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGED; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HERPES ZOSTER; HUMAN; MALE; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACY; PREVENTIVE HEALTH SERVICE; PROFESSIONAL STANDARD; RETROSPECTIVE STUDY; UNITED STATES;

AGED; AGED, 80 AND OVER; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION PROGRAMS; IOWA; MALE; PHARMACISTS; PROFESSIONAL ROLE; RETROSPECTIVE STUDIES;

EID: 63849091352     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.08030     Document Type: Article

References (15)

1. Kockler DR, McCarthy MW. Zoster vaccine live. Pharmacotherapy. 2007;27:1013-9.
2. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilization and costs in a group of U.S. health plans. Pharmacoeconomics. 2007;25:155-69.
3. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-37.
4. Gershon AA. Vaccination to prevent zoster in the elderly. Epidemiol Infect. 2007;135:883-6.
5. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44:1280-8.
6. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
7. Zostavax [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.: 2007.
8. Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of zoster vaccine. Accessed at www.cdc.gov/vaccines/ recs/provisional/downloads/zoster-11-20-06.pdf, January 18, 2008.
9. Grabenstein JD, Guess HA, Hartzema AG, et al. Effect of vaccination by community pharmacists among adult prescription recipients. Med Care. 2001;39:340-8.
10. Anonymous. The shingles vaccine: Why hasn't it caught on? The cost and other factors are to blame. Harv Health Lett. 2007;32:1-2.
11. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317-25.
12. West DS, ed. NCPA-Pfizer Digest 2007. Alexandria, VA: National Community Pharmacists Association; 2007.
13. Gardner JS. A practical guide to establishing vaccine administration services in community pharmacies. J Am Pharm Assoc. 1997;NS37:683-93.
14. McDonough RP, Doucette WR. Using personal selling skills to promote pharmacy services. J Am Pharm Assoc. 2003;43:363-74.
15. Centers for Medicare and Medicaid Services. Reimbursement for vaccines and vaccine administration under Medicare Part D. Accessed at www.cms.hhs.gov/MLNMattersArticles/downloads/SE0727.pdf, January 18, 2008.